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Research Article
Introduction
Cervical cancer is the second most common type of cancer 
associated with high mortality in women besides breast 
cancer, especially in regions with low human development 
index.1 Reduced incidence of cervical cancer in regions 
with a high human development index is mainly a result of 
the availability of Pap smear screening.1,2 However, cervi-
cal cancer is still one of the major types of cancer that 
contributes to cancer-associated mortality because cancer 
metastasis occurs in both early- and late-detected patients. 
Radiotherapy is the most commonly used treatment, and 
chemotherapy using cisplatin has been used as adjuvant to 
improve the performance of radiotherapy.3 Nevertheless, 
the outcome of current therapy is still poor, with no further 
improvement in survival and toxicity.2 Thus, exploring 
novel cytotoxic agents that cause minimal side effects is 
essential.
Natural antioxidants, including flavonoids and polyphe-
nols, derived from herbal extracts have gained increasing 
interest as powerful sources of safe chemopreventive and 
chemotherapeutic agents for cervical cancer. These antioxi-
dants were found to specifically target cervical cancer cells 
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Abstract
Flavokawain B (FKB) is known to possess promising anticancer abilities. This is demonstrated in various cancer cell lines 
including HeLa cells. Cervical cancer is among the most widely diagnosed cancer among women today. Though FKB has 
been shown to be effective in treating cancer cells, the exact molecular mechanism is still unknown. This study is aimed 
at understanding the effects of FKB on HeLa cells using a microarray-based mRNA expression profiling and proteome 
profiling of stress-related proteins. The results of this study suggest that FKB induced cell death through p21-mediated cell 
cycle arrest and activation of p38. However, concurrent activation of antioxidant-related pathways and iron sequestration 
pathway followed by activation of ER-resident stress proteins clearly indicate that FKB failed to induce apoptosis in HeLa 
cells via oxidative stress. This effect implies that the protection of HeLa cells by FKB from H2O2–induced cell death is via 
neutralization of reactive oxygen species.
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via induction of apoptosis, growth arrest, and inhibition of 
signal transduction pathways.4 Among the antioxidants, chal-
cones are one of the members of the flavonoid family with 
promising antitumor potential. The molecular structure of 
chalcones is 2 aromatic rings connected by an unsaturated 
3-carbon bridge. Edible plants such as kava-kava are a great 
source of chalcone, and chemical synthesis by the Claisen-
Schmidt condensation method has made the large-scale pro-
duction of chalcone for future therapeutic application 
possible.5 Several chalcones such as the 1,3-diphenylpropen-
1-one chalcone family have been tested, with cytotoxicity 
against cervical cancer attributed to their inhibitory effect on 
proteasomal activity.6,7 Flavokawain is one type of chalcone 
with multiple bioactivities, including anti-inflammatory, 
antioxidant, and antitumor activities. There are 3 types of fla-
vokawains—namely, flavokawain A, B, and C. Among them, 
flavokawain B (FKB) is the most well studied and possesses 
the greatest sensitivity against most of the evaluated cancer 
cell lines compared with flavokawain A and C.5FKB was 
reported to be a more potent inhibitor of hepatoblastoma 
HepG2 cells than cervical cancer HeLa cells via inhibition of 
intracellular antioxidants GSH and SOD2 and subsequently 
promoted intracellular oxidation and apoptosis.8 However, 
the detailed cytotoxicity of FKB on HeLa cells has not been 
well studied. To understand the flavokawain-regulated mech-
anism in HeLa cells, this study evaluated the gene expression 
profile of FKB-treated HeLa cells.
Materials and Method
Preparation of FKB and HeLa Cells
FKB was synthesized, purified, and characterized accord-
ing to our previous report.9 Cervical cancer HeLa cells were 
purchased from ATCC (ATCC, USA) and cultured in 
RPMI-1640 (Sigma, USA) supplemented with 10% fetal 
bovine serum (GE Healthcare Life Sciences, USA) in a 
37°C incubator with 5% CO2.
MTT Cell Viability Assay
Viability of FKB-treated HeLa cells was screened by the 
MTT cell viability assay according to Mosmann.10 Briefly, 
HeLa cells (8 × 104 cells/mL) were seeded in a 96-well plate 
overnight. Then, FKB was serial diluted (ranging between 
100.00 and 1.56 µM), applied to the HeLa cells, and further 
incubated for 72 hours. Untreated control HeLa cells were 
prepared concurrently. After that, MTT solution (5 mg/mL) 
was added to all wells and further incubated for 3 hours. 
After the solution was discarded, the purple crystals were 
solubilized with 100 µL of dimethyl sulfoxide, and the 
absorbance was read at a wavelength of 570 nm using a 
µQuant plate reader (Bio-tek Instruments, USA). The per-
centage of cell viability was calculated by dividing the 
absorbance of the sample by the absorbance of the control. 
The concentration that inhibited 50% of HeLa cell viability 
was obtained from the sigmoid curve of cell viability versus 
flavokawain concentration.
Cell Treatment
Based on the IC50 (half-maximal inhibitory concentration) 
value obtained from the MTT assay, HeLa cells were treated 
with 17.5 µM of FKB in 6-well plate and incubated for 24 
and 48 hours. After the incubation time, untreated control 
and FKB-treated HeLa cells were harvested, washed, and 
subjected to the following bioassays.
Flow Cytometry Analyses
Flow cytometry was used to evaluate the cell cycle profile, 
apoptosis, and mitochondrial membrane potential of FKB-
treated HeLa cells. The cell cycle profile of untreated con-
trols and HeLa cells treated with FKB for 48 hours was 
evaluated using BD CycletestTM Plus DNA kit according to 
the manufacturer’s protocol. Briefly, harvested control and 
treated HeLa cells were incubated with 250 µL of Solution 
A (10 minutes), followed by 200 µL of trypsin inhibitor and 
RNase buffer Solution B (10 minutes), and finally by 200 
µL of propidium iodide (PI; 10 minutes). The samples were 
then analyzed by BD FACSCalibur using BD CellQuest Pro 
software (BD, USA). For apoptosis quantification, BD 
Annexin-V/PI apoptosis kit (BD, USA) was used according 
to the manufacturer’s protocol. In brief, harvested control 
and FKB-treated HeLa cells were incubated with 5 µL of 
AnnexinV-FITC and 5 µL of PI for 15 minutes. Then, the 
samples were topped up with 400 µL of binding buffer and 
analyzed by BD FACSCalibur using BD CellQuest Pro 
software (BD, USA). BD MitoScreen JC-1 kit was used for 
quantification of mitochondrial membrane potential. In 
brief, harvested control and FKB-treated HeLa cells were 
incubated with 500 µL of JC-1 working solution (15 min-
utes), washed, and resuspended with 500 µL of assay buffer. 
The samples were then analyzed by BD FACS Calibur 
using BD CellQuest Pro software (BD, USA).
Gene Expression Profiling Using Microarray
Differential gene expression of untreated HeLa cells and 
HeLa cells treated with FKB for 48 hours was assayed by 
Agilent one color microarray using a human gene expres-
sion v2 microarray chip (Agilent Technologies, USA). In 
brief, RNA was extracted from control and FKB-treated 
HeLa cells by Qiagen RNeasy plus mini kit (Qiagen, USA). 
Then, the quantity and quality of extracted RNA were tested 
by nano-drop spectrometer (Eppendorf, USA) and 2100 
Bioanalyzer with RNA pico chip (Agilent Technologies, 
USA). Three biological replicates of control and treated 
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HeLa cell RNA with bioanalyzer RIN number >9 were sub-
jected to microarray using SurePrint G3 Human Gene 
Expression 8 × 60K v2 microarray kit (Agilent Technologies, 
USA) according to the manufacturer’s protocol and scanned 
with Agilent DNA microarray scanner. Differential expres-
sion comparison between untreated controls and HeLa cells 
treated with FKB for 48 hours was analyzed by GeneSpring 
GX (Agilent Technologies, USA). Genes based on gene 
ontology with expression level and with significant changes 
as determined by Student’s t-test (P< .05) and fold changes 
>2 are presented in this study. The results from this microar-
ray study can be accessed via NCBI GEO using the acces-
sion number GSE72974.
Quantitative Reverse Transcriptase Real-Time 
Polymerase Chain Reaction (qRT-PCR)
Total RNA subjected to microarray analysis was also vali-
dated by qRT-PCR. Briefly, the 1-µg RNA was converted 
to cDNA using high-capacity cDNA reverse transcription 
kit according to manufacturer’s protocol (LifeTechnology, 
USA). Next, the RT-PCR reaction to quantify differential 
expression of DNA-damage-inducible transcript 3 
(DDIT3), hemeoxygenase (decycling)1 (HMOX1), growth 
arrest and DNA-damage-inducible beta (GADD45B), cata-
lase (CAT), and glutathione peroxidase 3 (GPx3) between 
untreated control and FKB-treated HeLa cells was per-
formed using Sybr green RT-PCR master mixes 
(LifeTechnologies, USA) on the iQ5 (Bio-Rad, USA). 
Forward and reverse sequence of the target genes (DDIT3, 
HMOX1, GADD45B, CAT, and GPx3) and housekeeping 
genes hypoxanthine phosphoribosyltransferase (HPRT), 
β-actin (ACTB), and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) are listed in Table 1. The PCR condition 
was as follows: 1 cycle of 50°C for 2 minutes for UDG 
(Uracil-DNA Glycosylase) activation, 1 cycle of 95°C for 
2 minutes for DNA polymerase activation, 40 cycles of 
95°C for 2 s for denature, and 52°C for 30 s for anneal and 
extend. All samples were assayed in triplicate, and the 
none-template controls were prepared. The quantity of tar-
get and housekeeping genes ACTB, HPRT, and GAPDH 
were calculated according to a standard curve, and the 
expressions of DDIT3, HMOX1, GADD45B, and GPx3 
were measured by Bio-Rad CFX Manager (Bio-Rad, 
USA). The expression levels of FKB-treated cells were 
compared with those of untreated controls. Table 1 illus-
trates the name of the gene, accession number, and sequence 
of primers used in this assay (http://pga.mgh.harvard.edu/
primerbank/).
Proteome Profiler Antibody Human Cell Stress 
Array
Differential expression of cell stress–related protein 
between untreated controls and HeLa cells treated with 
FKB for 48 hours were evaluated using proteome profiler 
antibody human cell stress array (R&D Systems, USA) 
according to the manufacturer’s protocol. Briefly, protein 
was extracted from harvested cells by lysis buffer, and 
concentration was standardized with Bradford assay and 
blocked on membranes with spotted antibodies at 4°C 
overnight. Then, the membranes were washed and incu-
bated with biotinylated detection antibodies for 2 hours at 
room temperature followed by streptavidin–horseradish 
peroxidase/chemiluminescence substrate. The mem-
branes were then scanned and imaged by ChemiDocx 
XRS+ (BioRad, USA) and Image Lab software (BioRad, 
USA).
Table 1. Gene Name, Accession Number, and Sequence of Primers Used in Real-Time PCR to Validate the Microarray Results.
Gene Name Accession Number Sequence
HMOX1 NM_002133.2 F: 5-AAGACTGCGTTCCTGCTCAAC-3
R: 5-AAAGCCCTACAGCAACTGTCG-3
DDIT3 NM_001195057.1 F: 5-GAACGGCTCAAGCAGGAAATC-3
R: 5-TTCACCATTCGGTCAATCAGAG-3
GPX3 NM_002084.3 F: 5-AGAGCCGGGGACAAGAGAA-3
R: 5-ATTTGCCAGCATACTGCTTGA-3
GADD45A NM_001924.3 F: 5-GAGAGCAGAAGACCGAAAGGA-3
R: 5-CAGTGATCGTGCGCTGACT-3
CAT NM_001752.3 F:5-TGGGATCTCGTTGGAAATAACAC-3
R:5-TCAGGACGTAGGCTCCAGAAG-3
ACTB NM_001101.3 F: 5-AGAGCTACGAGCTGCCTGAC-3
R: 5-AGCACTGTGTTGGCGTACAG-3
GAPDH NM_002046.4 F: 5- GGATTTGGTCGTATTGGGC-3
R: 5- TGGAAGATGGTGATGGGATT-3
18S RRNA HQ387008.1 F: 5- GTAACCCGTTGAACCCCATT-3
R: 5- CCATCCAATCGGTAGTAGCG -3
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Superoxide Dismutase (SOD) and Glutathione 
(GSH) Quantification
The extracted protein for control and FKB-treated HeLa cells 
that were standardized with Bradford assay was quantified for 
SOD and GSH contents. For SOD, 100 µL of extracted pro-
tein was mixed with 200 µL of working solution (0.1 mol/L 
phosphate buffer, 0.15 mg/mL sodium cyanide in 0.1 mol/L 
ethylenediaminetetraacetic acid, 1.5 mmol/L nitrobluetetrazo-
lium and 0.12 mmol/L riboflavin). GSH was quantified using 
a GSH assay kit (Sigma, USA), where 10 µL of protein was 
added with 150 µL of working solution (1.5 mg/mL DTNB, 6 
U/mL GSH reductase, and 1× assay buffer). After 5 minutes 
of incubation, 50 µL of NADPH solution (0.16 mg/mL) was 
added to the mixture. The absorbance for SOD and GSH were 
measured using ELISA plate reader (Bio-Tek Instruments, 
USA) at respective wavelengths of 560 and 420 nm.
Reactive H2O2 Cotreatment
Control and FKB (17.5 µM)-treated HeLa cells (48 hours of 
incubation) were further cultured in the presence of 125 µM 
H2O2 for 3 hours.
11 After that, cell viability of these H2O2-
challenged control and FKB-treated HeLa cells was quanti-
fied using the MTT assay. In addition, expression of CAT 
and HMOX mRNA was quantified using qRT-PCR. Levels 
of SOD, GSH, and ROS were quantified according to the 
above methods.
ROS Quantification
ROS levels of FKB-treated HeLa cells, untreated HeLa cells, 
H2O2-treated HeLa cells, and FKB + H2O2–treated HeLa 
cells were quantified using DCFDA-cellular reactive oxygen 
species (ROS) detection assay kit (Abcam, USA). In brief, 
after 48 hours of incubation, the control and FKB-treated 
cells in a 96-well plate were stained with 25 µM DCFDA for 
45 minutes at 37°C. After that, all wells were washed, and the 
fluorescent signal was measured at excitation (Ex)/emission 
(Em) = 485/535 nm using Arzoskan Flash microplate fluo-
rometer (Thermo Fisher Scientific, USA).
Statistical Analysis
All assays were tested with 3 biological replicates and 
expressed as mean ± SD. Results with statistical signifi-
cance (P< .05) were assayed by Student’s t-test compared 
with untreated controls.
Results
FKB-Induced Cytotoxicity Against HeLa Cells
Cytotoxicity of FKB on HeLa cells was tested using the 
MTT assay. After 72 hours of incubation, the IC50 value of 
FKB on HeLa cells was 17.5 µM. This concentration has 
been used for the subsequent analysis to understand the 
response of HeLa cells post–FKB treatment.
FKB-Induced G2/M Phase Arrest and Apoptosis 
Through Loss of Membrane Potential
To elucidate the suppression of cell growth and mode of cell 
death induced by FKB on HeLa cells, flow cytometry cell 
cycle analysis, Annexin V-FITC/PI apoptosis assay, and JC-1 
membrane potential quantification were carried out. HeLa 
cells were arrested by FKB at the G2/M phase, indicated by a 
3-fold higher population of cells accumulated in the G2/M 
phase compared with untreated controls after 48 hours of 
treatment (Figure 1).
On the other hand, FKB was found to induce cell death 
via apoptosis indicated by both Annexin V/PI and JC-1 
flow cytometry assays. In terms of Annexin V/PI apopto-
sis assay, FKB-treated HeLa cells were recorded with 
~39.86% and ~13.73% of cells undergoing early apopto-
sis and late apoptosis stages, respectively. In terms of the 
JC-1 assay, which measured the membrane potential of 
mitochondria, FKB treatment was found to induce loss of 
mitochondrial membrane potential in approximately 50% 
of treated HeLa cells.
FKB Differentially Regulated mRNA Expression 
of Cell Cycle, Apoptosis, Cell Stress, and MAPK 
Pathways
A microarray was used to evaluate the differentially regu-
lated mRNA expression between control and FKB-treated 
HeLa cells. A total of 72 differential expression (>2.5-
fold change in FKB-treated compared with untreated 
HeLa cells) genes related to apoptotic, cell cycle, Nrf2, 
and MAPK pathways were identified in this study. Tables 
2 and 3 summarize the regulated genes promoting cell 
death and cell survival, respectively. Among the regulated 
genes promoting cell death, 32 were downregulated and 
15 were upregulated. The majority of the upregulated 
genes were from cell cycle–related pathways (Table 2). 
On the other hand, 7 were downregulated, whereas 15 
were upregulated in the genes that promote survival of the 
FKB-treated HeLa cells. Among the regulated genes pro-
moting cell survival, the majority were related to antioxi-
dant response.
Changes in gene expression detected in the microarrays 
(DDIT3 from the MAPK pathway, GPx3, HMOX1, CAT 
from the oxidative pathway, and DDIT3 from the apoptosis 
pathway) were validated using qRT-PCR. All these genes 
showed upregulation with similar fold change between 
microarray and qRT-PCR (Figure 2).
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FKB Differentially Regulated Protein Expression 
of the Cell Stress–Related Pathway
Because proapoptotic and antioxidant-related genes were 
observed in FKB-treated HeLa cells, differential protein 
expression of the cell stress–related pathway was validated 
using Human Cell Stress Proteome Profiler Antibody Array. 
Among the targets, cytochrome C, phospho-p38 alpha 
(T180/Y182), SOD2, phospho-HSP27 (S78/S82), and 
HSP70 were found to be significantly regulated (>2.5-fold 
Figure 1. A. Flow cytometry analysis of the JC-1 assay (mitochondrial membrane potential) in FKB-treated HeLa cells and untreated 
HeLa cells. R1:R2 represents the monomers to aggregates ratio. B. Flow cytometry analysis of Annexin V assay in FKB-treated HeLa 
cells and untreated HeLa cells. Upper left quadrant represents the percentage of late apoptosis cell population, and the lower left 
quadrant represents the early apoptosis cell population. C. Flow cytometry analysis of the cell cycle assay in FKB-treated HeLa cells 
and untreated HeLa cells. Data represent mean ± SEM for 3 sets of replicates. *P< .05.
Abbreviation: FKB, flavokawain-B.
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Table 2. Genes That Are Differentially Expressed (>2.5-fold, P< .05) and Involved in Promoting Cell Death in FKB-Treated HeLa 
Cells Compared With Untreated Controls.
Gene Bank Gene Symbol Gene Name Fold Change >2.5
Proapoptosis
NM_002485 NBN nibrin −3.44
NM_002546 TNFRSF11B tumor necrosis factor receptor superfamily, member 11b −3.01
NM_001289072 HELLS helicase, lymphoid-specific −2.58
NM_182972 IRF2 interferon regulatory factor 2 −2.52
NM_004031 IRF7 interferon regulatory factor 7 2.54
NM_005427 TP73 tumor protein p73 2.74
NM_021127 PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 2.76
NM_005658 TRAF1 TNF receptor-associated factor 1 3.09
NM_148965 TNFRSF25 tumor necrosis factor receptor superfamily, member 25 3.20
NM_003806 HRK harakiri, BCL2 interacting protein 3.22
NM_020396 BCL2L10 BCL2-like 10 (apoptosis facilitator) 3.38
NM_015675 GADD45B growth arrest and DNA-damage-inducible, beta 4.06
NM_006705 GADD45G growth arrest and DNA-damage-inducible, gamma 30.80
Cell cycle arrest
NM_153255 MCM9 minichromosome maintenance complex component 9 −5.06
NM_057749 CCNE2 cyclin E2 −4.78
NM_004091 E2F2 E2F transcription factor 2 −4.33
NM_001527 HDAC2 histone deacetylase 2 −4.31
NM_001166419 HDAC8 histone deacetylase 8 −3.09
NM_006044 HDAC6 histone deacetylase 6 −2.75
NM_182751 MCM10 minichromosome maintenance complex component 10 −2.74
NM_002800 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 −2.68
NM_006739 MCM5 minichromosome maintenance complex component 5 −2.55
NM_002915 RFC3 replication factor C (activator 1) 3, 38kDa −2.55
NM_022111 CLSPN claspin −2.51
NM_078467 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 4.43
Pro-oxidation
NM_003039 SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 −17.32
NM_018057 SLC6A15 solute carrier family 6 (neutral amino acid transporter), member 15 −8.53
NM_005233 EPHA3 EPH receptor A3 −6.42
NM_020342 SLC39A10 solute carrier family 39 (zinc transporter), member 10 −3.81
NM_173815 CES4A carboxylesterase 4A −3.60
NM_005573 LMNB1 lamin B1 −3.56
NM_004495 NRG1 neuregulin 1 −3.47
NM_001135147 SLC39A8 solute carrier family 39 (zinc transporter), member 8 −3.03
NM_001025195 CES1 carboxylesterase 1 2.91
MAPK
NM_002758 MAP2K6 mitogen-activated protein kinase kinase 6 −4.99
NM_005739 RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) −3.78
NM_006609 MAP3K2 mitogen-activated protein kinase kinase kinase 2 −3.09
NM_002007 FGF4 fibroblast growth factor 4 −2.96
NM_003239 TGFB3 transforming growth factor, beta 3 −2.72
NM_002738 PRKCB protein kinase C, beta −2.71
NM_002397 MEF2C myocyte enhancer factor 2C −2.67
NM_005228 EGFR epidermal growth factor receptor −2.57
NM_005207 CRKL v-crk avian sarcoma virus CT10 oncogene homolog-like −2.55
NM_004417 DUSP1 dual specificity phosphatase 1 3.24
NR_002834 DUSP5 dual specificity phosphatase 5 3.79
NM_001963 EGF epidermal growth factor 5.20
NM_004083 DDIT3 DNA-damage-inducible transcript 3 10.81
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change in FKB-treated compared with untreated HeLa 
cells; Figure 3).
FKB Enhanced the GSH and SOD Levels in 
Treated HeLa Cells
Cellular levels of GSH and SOD were compared between 
control and FKB-treated HeLa cells. The result showed that 
FKB-treated HeLa cells contained 1.24- and 3.20-fold 
higher expression of SOD and GSH, respectively, compared 
with untreated control cells (Figure 4).
FKB Protects HeLa Cells From H2O2-Induced 
Cell Death
H2O2 reduced viability of HeLa cells after 3 hours of incu-
bation. In contrast, FKB-pretreated HeLa cells were also 
observed with similar percentage of cell viability after 
incubating with H2O2 for 3 hours, which is higher than the 
viability of FKB-treated HeLa cells (~50% of viability; 
Figure 5).
To understand the contribution of antioxidant mecha-
nisms in protecting FKB-treated HeLa cells from H2O2-
induced cell death, mRNA expression of HMOX and CAT 
were quantified by qRT-PCR. HeLa cells treated with 
H2O2 were observed with downregulation of CAT gene 
and were unchanged for the expression of HMOX gene 
(Figure 6). On the other hand, FKB + H2O2–treated HeLa 
cells were observed with overexpression of HMOX and 
CAT genes. Both H2O2 only and FKB + H2O2–treated 
HeLa cells were recorded with lower SOD and GSH 
activities compared with FKB-treated HeLa cells. More 
interestingly, H2O2-treated HeLa cells had even lower 
SOD activity when compared with the FKB + H2O2–
treated HeLa cells (Figure 7).
Activation of Antioxidant by FKB Neutralizes 
H2O2-Induced ROS in HeLa Cells
Untreated HeLa cells were recorded with lower levels of 
ROS in comparison to FKB-treated HeLa cells. However, 
3 hours of H2O2 treatment drastically raised ROS levels in 
the HeLa cells. On the other hand, FKB + H2O2 treatment 
Table 3. Genes That Are Differentially Expressed (>2.5-fold, P< .05) and Involved in the Defence Mechanism for Cell Survival in 
FKB-Treated HeLa Cells Compared With Untreated Controls.
Gene Bank Gene Symbol Gene Name Fold Change >2.5
Antiapoptosis
NM_001003940 BMF Bcl2 modifying factor −6.31
NM_003879 CFLAR CASP8 and FADD-like apoptosis regulator −2.88
NM_001164410 CDK5 cyclin-dependent kinase 5 −2.52
NM_022161 BIRC7 baculoviral IAP repeat containing 7 3.74
Cell cycle progress
NM_145663 DBF4 DBF4 zinc finger −4.03
NM_033331 CDC14B cell division cycle 14B −2.78
Antioxidant
NM_001286789 CBR1 carbonyl reductase 1 −3.62
NM_001175 ARHGDIB Rho GDP dissociation inhibitor (GDI) beta −2.89
NM_001945 HBEGF heparin-binding EGF-like growth factor 2.65
NM_001074 UGT2B7 UDP glucuronosyltransferase 2 family, polypeptide B7 2.79
NM_001144070 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 2.86
NM_001135195 SLC39A5 solute carrier family 39 (zinc transporter), member 5 2.95
NM_001045 SLC6A4 solute carrier family 6 (neurotransmitter transporter), member 4 3.08
NM_012212 PTGR1 prostaglandin reductase 1 3.26
NR_046439 MAFF v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F 3.80
NM_000713 BLVRB Biliverdin reductase B (flavin reductase (NADPH)) 4.22
NM_001964 EGR1 early growth response 1 4.22
NM_002084 GPX3 glutathione peroxidase 3 (plasma) 4.44
NM_002133 HMOX1 hemeoxygenase (decycling) 1 25.97
MAPK
NM_002506 NGF nerve growth factor (beta polypeptide) 2.67
NM_005347 HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 2.71
NM_002754 MAPK13 mitogen-activated protein kinase 13 3.78
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was found to lead to a greater reduction in ROS levels 
(Figure 8).
Discussion
Flavokawains, especially FKB, have been well documented 
to have great potential as anticancer agents. Among flavoka-
wains A, B, and C, FKB was the most popular chalcone 
tested for its cytotoxicity on various cancer cell lines. 
Generally, FKB possessed greater cytotoxicity, with lower 
IC50 value against most of the tested cancerous cell lines 
compared with flavokawain A.5Similar to the effect on most 
of the other cancer cells, including osteosarcoma12 and oral 
carcinoma,13FKBwas found to induce apoptosis and G2/M 
cell cycle arrest in HeLa cells by flow cytometry analyses 
(Figure 1). Furthermore, FKB-treated HeLa cells were also 
recorded with loss of mitochondrial membrane potential. 
These results have suggested that FKBcan induce cell cycle 
arrest and apoptosis as well as possess the potential anticer-
vical cancer effect similar to the effect on other types of can-
cer cells. However, Zhou et al8 reported that HepG2 liver 
cancer cells were more sensitive than HeLa cervical cancer 
cells in inducing oxidative stress–mediated cell death via 
regulation of the MAPK signaling pathway. A previous 
report has shown that unlike flavokawain A, FKBinduced 
cell cycle arrest and apoptosis in cancer cells regardless of 
p53 status. On the other hand, our study on breast cancer cell 
lines has further shown that FKBwas more sensitive to p53-
mutated MDA-MB-231 than p53 wild-type MCF-7 cell 
lines via p38 MAPK and p53 pathways, respectively. 
However, because both HepG2 and HeLa cell lines are p53 
wild-type cancerous cells,13 differential regulation resulting 
from the presence or absence of p53 protein may not be the 
major concern contributing to the selectivity of FKBto 
HepG2 and HeLa cell lines. In this study, the IC50 value of 
FKBin HeLa cells was ~17.5 µM, which is slightly higher 
than the IC50 value in HepG2 (15.3 µM) as reported by Zhou 
et al.8 To understand the detailed mechanism that contrib-
uted to the proapoptosis and defensive mechanisms of HeLa 
cells responding to the FKBtreatment, gene expression study 
using a microarray was carried out to identify the differen-
tially regulated genes between control and FKB-treated 
HeLa cells.
In the microarray study, differentially expressed genes 
(>2.5-fold compared with the control HeLa cells) that are 
related to apoptosis, cell cycle regulation, Nrf2 oxidative 
stress, and MAPK are listed in Tables 2 and 3 based on pro-
apoptotic and prosurvival regulation, indicating their roles 
in promoting or defending against cell death. As shown in 
the cell cycle analysis, FKB promoted G2/M arrest in HeLa 
cells, which was contributed by upregulation of p21 and 
downregulation of MCM9 and cyclin E2 (Table 2) without 
significant regulation of p53, which was similar to the effect 
on the osteosarcoma cell lines.12 Upregulation of p21 may 
be contributed by the induction of EGF and downregulation 
of EGFR in the FKB-treated HeLa cells. EGF was previ-
ously reported to induce p21-mediated cell cycle arrest and 
apoptosis in squamous carcinoma via reduction of cell 
adhesion.14 Besides G2/M cell cycle arrest, FKB was also 
found to positively regulate proapoptotic-related and 
p38-activated genes. For example, Gadd45a and Gadd45b 
were the 2 most highly upregulated genes that related to 
apoptosis. Upregulation of p21 was believed to activate the 
proapoptotic proteins Gadd45a and Gadd45b that subse-
quently activate p38 and induce apoptosis.15,16 This was 
observed in our protein array and flow cytometry JC-1 
membrane potential analysis, where drastic upregulation of 
phosphor-p38 alpha (T180/Y182) and cytochrome c associ-
ated with loss of membrane potential were observed in 
FKB-treated HeLa cells. All these results clearly indicate 
that FKB induced p21-mediated G2/M arrest and induced 
apoptosis via activation of the p38 MAPK pathway.
Besides proapoptotic regulation, prosurvival defensive 
response, especially upregulation of the antioxidant response, 
was also observed in the FKB-treated HeLa cells. Zhou et al8 
and Hseu et al13 have previously reported that induction of 
oxidative stress in cancer cells, especially liver and oral can-
cer cell lines, via upregulation of ROS to deplete the Nrf2 
pathway after FKB treatment has been proposed as one of the 
important mechanisms to induce apoptosis in cancer. 
However, Zhou et al8 also reported that FKB was less effec-
tive in inducing apoptosis via depletion of reduced GSH in 
HeLa cells. Based on the microarray analysis, the overexpres-
sion of genes that regulate cellular antioxidants was much 
greater than that of the gene that promotes oxidative stress (11 
Figure 2. Validation of microarray results by RT-PCR for 
selected genes, HMOX-1, DDIT-3, GpX, Gadd45A, and CAT. 
The results represent the fold change of the genes in both 
microarray and RT-PCR. *P< .05.
Abbreviations: qRT-PCR, quantitative reverse transcriptase real-time 
polymerase chain reaction; HMOX1, hemeoxygenase (decycling)1; 
DDIT3, DNA-damage-inducible transcript 3; GPx3, glutathione 
peroxidase 3; GADD45B, growth arrest and DNA-damage-inducible 
beta; CAT, catalase.
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vs 1). Among the antioxidant genes, HMOX1 and GPx3 were 
the 2 most highly upregulated genes. HMOX1 is the down-
stream gene under Nrf2 that works in iron sequestration, 
which degrades pro-oxidant heme into ferrous iron, carbon 
monoxide, and biliverdin. Overexpression of HMOX1 in can-
cer, especially under the stress condition induced by chemo-
therapeutic drug treatment, was thought to balance and 
neutralize the redox cellular environment and subsequently 
contributed to the cellular resistance against chemotherapy 
and radiotherapy.17 GPx3 is an antioxidant enzyme that scav-
enges H2O2 in the presence of GSH,
18which was also found to 
be 3.2-fold higher in the FKB-treated HeLa cells. Besides, 
another antioxidant enzyme, SOD, especially SOD2 was also 
found to be significantly upregulated in the protein level. 
SOD2 plays an important role in reducing superoxide (O−•) to 
H2O2, which is further reduced to H2O by GPx in the presence 
of GSH as a cofactor.19 These results have given us the idea 
that GSH/GPx3, SOD, and HMOX1 collectively worked 
Figure 3. Comparison between the untreated and FKB-treated HeLa cells in proteome profiler analysis of cell stress proteins.
Abbreviations: FKB, flavokawain-B; SOD, superoxide dismutase.
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together as an antioxidant defensive mechanism to attenuate 
the oxidative stress induced by FKB treatment in the case of 
the cervical cancer cell line (Figure 9).
Activation of the antioxidant mechanism in HeLa cells in 
FKB treatment was also recorded with activation of heat 
shock proteins (HSP)70 and phosphorylated HSP27. HSPs 
are molecular chaperones that are induced by environmental 
stress to maintain the cellular balance, including survival. 
HSPs can be separated into high- and low-molecular-weight 
types, such as HSP70 and HSP27, respectively. 
Overexpression of HSP70 and HSP27 were observed in vari-
ous types of cancer, and this phenomenon was always 
associated with promotion of chemoresistance.20,21 Promotion 
of these HSPs by FKB in HeLa cells was not the same as the 
effect on oral cancer cells, which was associated with down-
regulation of HSP70.13
To confirm the activation of the antioxidant pathway by 
FKB in HeLa cells, untreated and FKB-treated HeLa cells 
were further incubated for 3 hours with H2O2. H2O2 has 
been previously reported to induce HeLa cell death via acti-
vation of mitochondria-dependent apoptosis by depleting 
Figure 4. SOD and GSH levels in FKB-treated HeLa cells and 
untreated HeLa cells. Data represent mean ± SEM for 3 sets of 
replicates. *P< .05.
Abbreviations: SOD, superoxide dismutase; GSH, glutathione; FKB, 
flavokawain-B.
Figure 5. Viability of FKB-treated HeLa cells, untreated HeLa 
cells, H2O2-treated HeLa cells, and FKB + H2O2-treated HeLa 
cells. Data represent mean ± SEM for 3 sets of replicates. *P< 
.05.
Abbreviation: FKB, flavokawain-B.
Figure 6. RT-PCR for selected genes, HMOX-1 and CAT of 
H2O2-treated HeLa cells (3 hours) and FKB + H2O2-treated 
HeLa cells. The results represent the fold change of the genes in 
both microarray and RT-PCR. *P< .05.
Abbreviations: RT-PCR, reverse transcriptase real-time polymerase 
chain reaction; HMOX1, hemeoxygenase (decycling)1; CAT, catalase; 
FKB, flavokawain-B.
Figure 7. SOD and GSH levels in H2O2-treated HeLa cells 
(3 hours) and FKB + H2O2–treated HeLa cells. Data represent 
mean ± SEM for 3 sets of replicates. *P< .05.
Abbreviations: SOD, superoxide dismutase; GSH, glutathione; FKB, 
flavokawain-B.
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cellular antioxidants and generation of ROS.11 Similar to 
the previous report, H2O2 reduced the viability, depleted the 
cellular antioxidant (suppression of CAT and HMOX 
mRNA expression and reduction of SOD and GSH activi-
ties), and drastically raised the ROS accumulation in HeLa 
cells. Conversely, FKB + H2O2–treated HeLa cells were 
observed with higher viability and lower ROS accumula-
tion. This effect may be a result of the engagement of anti-
oxidants, including HO-1, CAT, SOD, and GSH by FKB, 
which have been reported for cytoprotective roles against 
damage induced by oxidants such as H2O2.
22
The structure of flavokawains—that is, electrophilic α,β-
unsaturated carbonyl—has been proposed to contribute to 
both the promotion of the cancer cell antioxidant pathway 
via activating antioxidant transcription factor Nrf-2 gene 
and the upregulation of the HSP pathway, resulting in can-
cer cell survival.22 Thus, upregulation of these antioxidants 
and HSPs raises a concern of creating a resistant condition 
against all the other chemotherapeutic drugs that kill cervi-
cal cancer via generation of oxidative stress.
Conclusion
Chalcones, especially FKB, have been proposed as poten-
tial universal, natural anticancer agents. However, this 
study has raised the question of the suitability of using FKB 
in treating cervical cancer cells with HeLa cell lines as a 
model. Although FKB induced p21-mediated cell cycle 
arrest and activated p38, which promote apoptosis in HeLa 
cells, concurrent activation of antioxidant mechanisms fol-
lowed by overexpression of ER-resident stress protein 
HSP70 and phosphorylation of HSP27 (Figure 5) may 
account for possible resistance toward this treatment.
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